EnerSpar Corp. (TSE:NRX) has released an update.
NurExone Biologic Inc. has announced promising data for ExoPTEN, its nanodrug that demonstrates precise targeting of inflammation and injury sites, which is a crucial step towards commercial manufacturing. The study validated the use of NurExone’s exosomes for drug delivery and the quality of siRNA from its new GMP-compliant manufacturing partner. These advancements bring the company closer to clinical trials and potential commercialization of their non-invasive therapies for Central Nervous System injuries.
For further insights into TSE:NRX stock, check out TipRanks’ Stock Analysis page.
